Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors.

Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors.

Bortezomib and the other licensed 20S proteasome inhibitors show robust activity against liquid tumors like multiple myeloma, but have disappointed against solid tumors including ovarian cancer. Consequently, interest is mounting in alternative non-peptide based drugs targeting the proteasome's...

Full description

Saved in:
Bibliographic Details
Main Authors: Ravi K Anchoori, Logan George, Ssu-Hsueh Tseng, Brandon Lam, Srinidhi Polkampally, Anjali D Amiano, Palmer Foran, Hannah Tsingine, Harideep Samanapally, Fernanda Carrizo Velasquez, Samarjit Das, Deyin Xing, Ahmad Bin Salam, Balasubramanyam Karanam, Chien-Fu Hung, Richard B S Roden
Format: article
Language:EN
Published: Public Library of Science (PLoS) 2021
Subjects:
Medicine
R
Science
Q
Online Access:https://doaj.org/article/a191fb5eadb24586b1e67b55b0cdb07d
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/a191fb5eadb24586b1e67b55b0cdb07d

Similar Items